FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802796377> ?p ?o ?g. }

• W2802796377 endingPage "1565" @default.
• W2802796377 startingPage "1557" @default.
• W2802796377 abstract "Abstract DS‐2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection. The aim of this study was to assess the safety, tolerability, pharmacokinetics, and effects on normal gastrointestinal microbiota groups of single daily oral ascending doses of DS‐2969b in healthy subjects. The study enrolled 6 sequential ascending dose cohorts (6 mg, 20 mg, 60 mg, 200 mg, 400 mg, and 600 mg). In each cohort, 6 subjects were administered DS‐2969b and 2 subjects were administered matching placebo. DS‐2969b was safe and well tolerated at all dose levels examined. All adverse events related to DS‐2969b were mild to moderate in severity and predominantly related to the gastrointestinal tract. DS‐2969a (free form of DS‐2969b) plasma concentrations increased with increasing doses; however, both the maximum serum concentration and area under the plasma concentration–time curve generally increased less than dose proportionally. DS‐2969a was predominantly eliminated in the urine, with feces as a minor route of elimination. While the overall proportion of DS‐2969a eliminated in the feces was low, target fecal levels sufficient for C. difficile eradication were achieved within 24 hours of administration with doses of 60 mg or higher. In exploratory analyses, DS‐2969b appeared to reduce bacterial counts in 8 of the 25 groups of normal intestinal microbiota examined, suggesting that DS‐2969b has only a mild effect on intestinal microbiota. Data from this study support and encourage further development of DS‐2969b as a novel treatment for C. difficile infection." @default.
• W2802796377 created "2018-05-17" @default.
• W2802796377 creator A5005921835 @default.
• W2802796377 creator A5013057554 @default.
• W2802796377 creator A5024548116 @default.
• W2802796377 creator A5027593818 @default.
• W2802796377 creator A5039475736 @default.
• W2802796377 creator A5041697078 @default.
• W2802796377 creator A5053118493 @default.
• W2802796377 creator A5056342150 @default.
• W2802796377 creator A5063918859 @default.
• W2802796377 creator A5091152891 @default.
• W2802796377 creator A5091397299 @default.
• W2802796377 date "2018-05-10" @default.
• W2802796377 modified "2023-10-14" @default.
• W2802796377 title "A Phase I, Single-Ascending-Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DS-2969b, a Novel GyrB Inhibitor" @default.
• W2802796377 cites W152943885 @default.
• W2802796377 cites W1981902086 @default.
• W2802796377 cites W2071054182 @default.
• W2802796377 cites W2083245084 @default.
• W2802796377 cites W2103858317 @default.
• W2802796377 cites W2113556993 @default.
• W2802796377 cites W2139607253 @default.
• W2802796377 cites W2142051176 @default.
• W2802796377 cites W2148982748 @default.
• W2802796377 cites W2154585806 @default.
• W2802796377 cites W2165050668 @default.
• W2802796377 cites W2166660180 @default.
• W2802796377 cites W2168453790 @default.
• W2802796377 cites W2300083402 @default.
• W2802796377 cites W2745216399 @default.
• W2802796377 cites W2761837134 @default.
• W2802796377 cites W2790582181 @default.
• W2802796377 doi "https://doi.org/10.1002/jcph.1151" @default.
• W2802796377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29746725" @default.
• W2802796377 hasPublicationYear "2018" @default.
• W2802796377 type Work @default.
• W2802796377 sameAs 2802796377 @default.
• W2802796377 citedByCount "6" @default.
• W2802796377 countsByYear W28027963772018 @default.
• W2802796377 countsByYear W28027963772019 @default.
• W2802796377 countsByYear W28027963772020 @default.
• W2802796377 countsByYear W28027963772021 @default.
• W2802796377 countsByYear W28027963772022 @default.
• W2802796377 crossrefType "journal-article" @default.
• W2802796377 hasAuthorship W2802796377A5005921835 @default.
• W2802796377 hasAuthorship W2802796377A5013057554 @default.
• W2802796377 hasAuthorship W2802796377A5024548116 @default.
• W2802796377 hasAuthorship W2802796377A5027593818 @default.
• W2802796377 hasAuthorship W2802796377A5039475736 @default.
• W2802796377 hasAuthorship W2802796377A5041697078 @default.
• W2802796377 hasAuthorship W2802796377A5053118493 @default.
• W2802796377 hasAuthorship W2802796377A5056342150 @default.
• W2802796377 hasAuthorship W2802796377A5063918859 @default.
• W2802796377 hasAuthorship W2802796377A5091152891 @default.
• W2802796377 hasAuthorship W2802796377A5091397299 @default.
• W2802796377 hasConcept C111113717 @default.
• W2802796377 hasConcept C112705442 @default.
• W2802796377 hasConcept C126322002 @default.
• W2802796377 hasConcept C142724271 @default.
• W2802796377 hasConcept C197934379 @default.
• W2802796377 hasConcept C204787440 @default.
• W2802796377 hasConcept C27081682 @default.
• W2802796377 hasConcept C2778375690 @default.
• W2802796377 hasConcept C2780026642 @default.
• W2802796377 hasConcept C2780512811 @default.
• W2802796377 hasConcept C2994496256 @default.
• W2802796377 hasConcept C501593827 @default.
• W2802796377 hasConcept C61716771 @default.
• W2802796377 hasConcept C71924100 @default.
• W2802796377 hasConcept C76318530 @default.
• W2802796377 hasConcept C86803240 @default.
• W2802796377 hasConcept C89423630 @default.
• W2802796377 hasConcept C90924648 @default.
• W2802796377 hasConcept C98274493 @default.
• W2802796377 hasConceptScore W2802796377C111113717 @default.
• W2802796377 hasConceptScore W2802796377C112705442 @default.
• W2802796377 hasConceptScore W2802796377C126322002 @default.
• W2802796377 hasConceptScore W2802796377C142724271 @default.
• W2802796377 hasConceptScore W2802796377C197934379 @default.
• W2802796377 hasConceptScore W2802796377C204787440 @default.
• W2802796377 hasConceptScore W2802796377C27081682 @default.
• W2802796377 hasConceptScore W2802796377C2778375690 @default.
• W2802796377 hasConceptScore W2802796377C2780026642 @default.
• W2802796377 hasConceptScore W2802796377C2780512811 @default.
• W2802796377 hasConceptScore W2802796377C2994496256 @default.
• W2802796377 hasConceptScore W2802796377C501593827 @default.
• W2802796377 hasConceptScore W2802796377C61716771 @default.
• W2802796377 hasConceptScore W2802796377C71924100 @default.
• W2802796377 hasConceptScore W2802796377C76318530 @default.
• W2802796377 hasConceptScore W2802796377C86803240 @default.
• W2802796377 hasConceptScore W2802796377C89423630 @default.
• W2802796377 hasConceptScore W2802796377C90924648 @default.
• W2802796377 hasConceptScore W2802796377C98274493 @default.
• W2802796377 hasFunder F4320321625 @default.
• W2802796377 hasIssue "12" @default.
• W2802796377 hasLocation W28027963771 @default.
• W2802796377 hasLocation W28027963772 @default.

• next